DUBLIN, Feb. 14, 2020 /PRNewswire/ --
Ap9
APPENDIX 3
DISCLOSURE FORMS
FORM 8.1(a)&(b)(i)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES
ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
|
Name of person dealing (Note 1)
|
Thomas C.
Freyman
|
|
Company dealt in
|
AbbVie
Inc.
|
|
Class of relevant security to which the
dealings being disclosed relate (Note 2)
|
US$0.01 Common
Stock
|
|
Date of dealing
|
13 February
2020
|
2.
INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
|
Long
|
Short
|
|
Number
|
|
(%)
|
Number
|
|
(%)
|
|
(1) Relevant securities
|
124,414
|
|
0.01%
|
|
|
|
|
(2) Derivatives (other than options)
|
0
|
|
|
|
|
|
|
(3) Options and agreements to purchase/sell
|
0
|
|
|
|
|
|
|
Total
|
124,414
|
|
0.01%
|
|
|
|
|
|
|
|
|
|
|
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
|
Class of relevant security:
|
Long
|
Short
|
|
Number
|
|
(%)
|
Number
|
|
(%)
|
|
(1) Relevant securities
|
N/A
|
|
|
(2) Derivatives (other than options)
|
|
|
|
(3) Options and agreements to purchase/sell
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
Ap10
3. DEALINGS (Note 4)
(a) Purchases and sales
|
Purchase/sale
|
Number of relevant securities
|
Price per unit (Note 5)
|
|
N/A
|
|
|
(b)
Derivatives transactions (other than options transactions)
|
Product name,
e.g. CFD
|
Nature of transaction
(Note 6)
|
Number of relevant securities
(Note 7)
|
Price per unit
(Note 5)
|
|
N/A
|
|
|
|
(c)
Options transactions in respect of existing relevant securities
(i)
Writing, selling, purchasing or varying
|
Product name,
e.g. call option
|
Writing, selling,
purchasing,
varying etc.
|
Number of securities
to which the option
relates (Note 7)
|
Exercise
price
|
Type, e.g.
American,
European etc.
|
Expiry
date
|
Option money
paid/received
per unit (Note 5)
|
|
N/A
|
|
|
|
|
|
|
(ii) Exercising
|
Product name,
e.g. call option
|
Number of securities
|
Exercise price per
unit (Note 5)
|
|
Stock
Options
|
23,705 shares
of common stock
|
US$29.23
|
(d)
Other dealings (including transactions in respect of new securities) (Note 4)
|
Nature of transaction
(Note 8)
|
Details
|
Price per unit
(if
applicable) (Note 5)
|
|
N/A
|
|
|
Ap11
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
|
Full details of
any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of
any relevant securities under any option referred to on this form
or relating to the voting rights or future acquisition or disposal
of any relevant securities to which any derivative referred to on
this form is referenced. If none, this should be
stated.
|
|
N/A
|
Is a Supplemental Form 8 attached? (Note 9)
NO
|
Date of disclosure
|
13 February
2020
|
|
Contact name
|
Manisha
Narasimhan, PhD
|
|
Telephone number
|
+ 1 862 261
7162
|
|
Name of offeree/offeror with which
acting in concert
|
Allergan plc
(NYSE: AGN)
|
|
Specify category and nature of
acting in concert status
|
Director of
Allergan plc
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/announcement-under-rule-8-1a-of-the-irish-takeover-rules-dealings-by-offerors-offerees-or-parties-acting-in-concert-with-them-for-themselves-or-for-discretionary-clients-301005072.html
SOURCE Allergan plc